STOCK TITAN

AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

AtriCure, Inc. (NASDAQ: ATRC) announced its fourth quarter and full year 2022 financial results will be released on February 21, 2023. An audio webcast and investor meetings are scheduled for the same date and also on February 14, 2023, at the BTIG MedTech Conference in Snowbird, Utah. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, with FDA-approved technologies such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System. These advancements cater to over 37 million Afib patients globally, cementing AtriCure's position in the medtech industry.

Positive
  • Scheduled release of fourth quarter and full year 2022 financial results on February 21, 2023.
  • Management will engage with investors at the BTIG MedTech Conference on February 14, 2023.
  • Innovative product offerings, including FDA-approved devices for Afib treatment, enhancing market position.
Negative
  • None.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 21, 2023, to discuss its fourth quarter and full year 2022 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.

AtriCure’s management is also scheduled to host investor meetings at the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023, in Snowbird, Utah.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Lynn Lewis or Marissa Bych

Gilmartin Group

Investor Relations

lynn@gilmartinir.com

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure release its fourth quarter and full year 2022 financial results?

AtriCure will release its financial results on February 21, 2023.

What is the purpose of the audio webcast scheduled for February 21, 2023?

The audio webcast is to discuss AtriCure's fourth quarter and full year 2022 financial results.

Where will the investor meetings take place?

The investor meetings will be held at the BTIG MedTech Conference in Snowbird, Utah, on February 14, 2023.

What products does AtriCure offer for atrial fibrillation treatment?

AtriCure offers FDA-approved devices including the Isolator® Synergy™ Ablation System and AtriClip® LAA Exclusion System.

How many people are affected by atrial fibrillation worldwide?

Atrial fibrillation affects more than 37 million people globally.

AtriCure, Inc.

NASDAQ:ATRC

ATRC Rankings

ATRC Latest News

ATRC Stock Data

1.48B
47.21M
3.18%
105.58%
3.43%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
MASON